Sirios Capital Management L P Buys 33,302 Shares of Abbott Laboratories $ABT

Sirios Capital Management L P grew its position in Abbott Laboratories (NYSE:ABT) by 57.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 91,728 shares of the healthcare product maker’s stock after buying an additional 33,302 shares during the quarter. Abbott Laboratories accounts for 1.6% of Sirios Capital Management L P’s holdings, making the stock its 21st largest holding. Sirios Capital Management L P’s holdings in Abbott Laboratories were worth $12,286,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of ABT. Cloud Capital Management LLC purchased a new position in shares of Abbott Laboratories in the 3rd quarter worth approximately $29,000. Guerra Advisors Inc acquired a new stake in shares of Abbott Laboratories during the third quarter worth about $31,000. Anfield Capital Management LLC raised its position in Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after buying an additional 104 shares during the last quarter. Delos Wealth Advisors LLC acquired a new position in Abbott Laboratories during the second quarter valued at $32,000. Finally, Bridge Generations Wealth Management LLC purchased a new stake in shares of Abbott Laboratories in the third quarter worth about $33,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling

In other news, VP John A. Jr. Mccoy sold 585 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the transaction, the vice president directly owned 24,628 shares of the company’s stock, valued at approximately $2,846,504.24. This represents a 2.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the sale, the executive vice president directly owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. This trade represents a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,055 shares of company stock worth $353,097 in the last three months. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Trading Down 0.1%

NYSE ABT opened at $107.99 on Friday. Abbott Laboratories has a 12 month low of $105.27 and a 12 month high of $139.06. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The company has a market capitalization of $187.66 billion, a price-to-earnings ratio of 29.03, a price-to-earnings-growth ratio of 1.72 and a beta of 0.74. The firm’s fifty day moving average price is $114.58 and its 200 day moving average price is $123.91.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. Abbott Laboratories’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Analysts Set New Price Targets

A number of analysts recently issued reports on ABT shares. Royal Bank Of Canada lowered their price target on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Sanford C. Bernstein decreased their price objective on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Daiwa Securities Group dropped their price target on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Argus reduced their target price on shares of Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Finally, The Goldman Sachs Group lowered their price target on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and an average target price of $136.16.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.